Statins: a repurposed drug to fight cancer

As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and ind...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 40; no. 1; pp. 241 - 33
Main Authors Jiang, Wen, Hu, Jin-Wei, He, Xu-Ran, Jin, Wei-Lin, He, Xin-Yang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.07.2021
BioMed Central
BMC
Subjects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biosynthesis
Breast cancer
Cancer
Cancer therapies
Cardiovascular disease
Cardiovascular diseases
Chemotherapy
Cholesterol
Clinical trials
Cytotoxicity
Drug Repositioning - methods
Drug repurposing
Drug therapy
Drugs
Epidemiology
Gastric cancer
Health aspects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Lipids
Liver cancer
Medical prognosis
Meta-analysis
Mevalonate pathway
Morbidity
Mortality
Neoplasms - drug therapy
Oncology, Experimental
Pancreatic cancer
Population
Prostate cancer
Review
Statins
Synergistic antitumor
Tumor microenvironment
Tumor Microenvironment - drug effects
Drug repurposing
Tumor microenvironment
Synergistic antitumor
Statins
Mevalonate pathway
Online AccessGet full text

Cover

Abstract As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.
AbstractList As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins. Keywords: Drug repurposing, Mevalonate pathway, Statins, Synergistic antitumor, Tumor microenvironment
Abstract As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.
ArticleNumber 241
Audience Academic
Author He, Xu-Ran
Jiang, Wen
Hu, Jin-Wei
Jin, Wei-Lin
He, Xin-Yang
Author_xml – sequence: 1
  givenname: Wen
  surname: Jiang
  fullname: Jiang, Wen
– sequence: 2
  givenname: Jin-Wei
  surname: Hu
  fullname: Hu, Jin-Wei
– sequence: 3
  givenname: Xu-Ran
  surname: He
  fullname: He, Xu-Ran
– sequence: 4
  givenname: Wei-Lin
  orcidid: 0000-0001-8011-2405
  surname: Jin
  fullname: Jin, Wei-Lin
– sequence: 5
  givenname: Xin-Yang
  surname: He
  fullname: He, Xin-Yang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34303383$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhoNU7If-AS9kQJAiTM3XZCZeCKVULRS8UK9DkjmZzTI7WZOM4L830611t4iEkJA85z3Jy3uKjqYwAUIvCb4gpBPvEmGYixpTUibmpKZP0AlpG1FLKcTR3v4Ynaa0xlgQSeQzdMw4w4x17AS9_Zp19lN6X-kqwnaO25Cgr_o4D1UOlfPDKldWTxbic_TU6THBi_v1DH3_eP3t6nN9--XTzdXlbW2FwLk2veHMEqt102vngEunW2OIY1gYK6nDtsXQNpozobsWLDOsa0AS2hPOuWFn6Gan2we9VtvoNzr-UkF7dXcQ4qB0zN6OoKQBQyRYILTlLcWGYyo4xY0sjaXgRevDTms7mw30FqYc9Xggengz-ZUawk_VlddSQYvA-b1ADD9mSFltfLIwjnqCMCdFm6Zhxc6mLejrR-g6zHEqVhVKUC4awshfatDlA35yofS1i6i6FC1lvKN8oS7-QZXRw8bbEgPny_lBwZu9ghXoMa9SGOfsw5QOwVf7jjxY8ScSBaA7wMaQUgT3gBCsltypXe5UyZ26y51abOoeFVm_BCssrvrxf6W_AW5N2CM
CitedBy_id crossref_primary_10_1016_j_bbrc_2024_150591
crossref_primary_10_3389_fphar_2024_1502791
crossref_primary_10_1016_j_metabol_2023_155659
crossref_primary_10_3390_cancers15153948
crossref_primary_10_1016_j_bbadis_2024_167458
crossref_primary_10_3390_cells11233790
crossref_primary_10_26787_nydha_2618_8783_2025_10_1_18_23
crossref_primary_10_3389_fphar_2023_1188926
crossref_primary_10_3389_fphar_2023_1136114
crossref_primary_10_3390_biology12020302
crossref_primary_10_3390_cimb47030201
crossref_primary_10_1007_s11864_024_01238_9
crossref_primary_10_3390_biomedicines10112834
crossref_primary_10_1186_s12964_024_01792_7
crossref_primary_10_3389_fonc_2024_1448966
crossref_primary_10_1152_ajpgi_00089_2023
crossref_primary_10_3390_cimb47010040
crossref_primary_10_3389_fphar_2024_1397602
crossref_primary_10_1038_s41401_025_01531_9
crossref_primary_10_3390_cancers15112959
crossref_primary_10_18231_j_ijpp_2023_051
crossref_primary_10_1016_j_ijpharm_2024_124473
crossref_primary_10_1007_s12032_024_02557_5
crossref_primary_10_1159_000533156
crossref_primary_10_1080_17512433_2022_2112178
crossref_primary_10_1016_j_bbamem_2023_184163
crossref_primary_10_3390_ijms25073641
crossref_primary_10_1155_2022_5618290
crossref_primary_10_3748_wjg_v29_i17_2571
crossref_primary_10_3390_ijms25031643
crossref_primary_10_3390_biomedicines12010109
crossref_primary_10_1007_s00592_022_01959_z
crossref_primary_10_1021_acsomega_2c05821
crossref_primary_10_3389_fmed_2021_737951
crossref_primary_10_1038_s41392_024_01808_1
crossref_primary_10_3390_cancers14112765
crossref_primary_10_1016_j_ejca_2022_11_025
crossref_primary_10_1038_s41568_022_00543_5
crossref_primary_10_3390_diagnostics14222579
crossref_primary_10_1186_s12885_023_10645_4
crossref_primary_10_3390_ijms25073874
crossref_primary_10_3390_cancers15205100
crossref_primary_10_1186_s12889_024_18498_7
crossref_primary_10_3389_fimmu_2022_946468
crossref_primary_10_3389_fimmu_2023_1141956
crossref_primary_10_1007_s00210_024_03151_2
crossref_primary_10_2174_1381612829666230913113808
crossref_primary_10_1186_s13046_024_03172_y
crossref_primary_10_3390_biom12091182
crossref_primary_10_1016_j_bbalip_2024_159578
crossref_primary_10_1016_j_cej_2025_159512
crossref_primary_10_1158_1535_7163_MCT_23_0458
crossref_primary_10_3390_ijms251910387
crossref_primary_10_1016_j_jpha_2023_08_019
crossref_primary_10_3390_ijms26010334
crossref_primary_10_1002_1878_0261_13720
crossref_primary_10_3389_fphar_2022_860546
crossref_primary_10_1038_s41392_024_01759_7
crossref_primary_10_1080_10717544_2022_2149898
crossref_primary_10_1186_s12967_022_03851_4
crossref_primary_10_1002_cnr2_2078
crossref_primary_10_1111_vco_13012
crossref_primary_10_1016_j_ijpx_2024_100249
crossref_primary_10_1002_ddr_22097
crossref_primary_10_3390_cells12192370
crossref_primary_10_1016_j_ejphar_2024_177087
crossref_primary_10_62347_KYIY8286
crossref_primary_10_1152_ajpcell_00331_2022
crossref_primary_10_3390_ph14121220
crossref_primary_10_1016_j_cpcardiol_2023_102103
crossref_primary_10_1016_j_advms_2023_07_002
crossref_primary_10_1016_j_eclinm_2023_102182
crossref_primary_10_3390_cancers14030714
crossref_primary_10_3390_ijms23020604
crossref_primary_10_1097_CAD_0000000000001533
crossref_primary_10_1111_bph_17309
crossref_primary_10_3389_fphys_2023_1250982
crossref_primary_10_1186_s43556_024_00204_z
crossref_primary_10_1016_j_ijbiomac_2024_134835
crossref_primary_10_1038_s41388_022_02407_6
crossref_primary_10_1111_vco_12946
crossref_primary_10_3390_ijms242316814
crossref_primary_10_1016_j_molliq_2022_120717
crossref_primary_10_1186_s12944_022_01734_7
crossref_primary_10_3389_fphar_2022_1108776
crossref_primary_10_2147_IJN_S400495
crossref_primary_10_3390_nu15194245
crossref_primary_10_1016_j_gendis_2024_101285
crossref_primary_10_1016_j_cej_2023_142160
crossref_primary_10_1038_s41392_023_01510_8
crossref_primary_10_3390_ph15050589
crossref_primary_10_1016_j_ijrobp_2023_05_031
crossref_primary_10_1097_JS9_0000000000001582
crossref_primary_10_1186_s40246_024_00688_4
crossref_primary_10_1038_s44355_025_00020_4
crossref_primary_10_1016_j_intimp_2024_112243
crossref_primary_10_1155_2022_7827821
crossref_primary_10_32604_or_2024_053337
crossref_primary_10_1016_j_omtn_2022_08_028
crossref_primary_10_3390_diseases11020086
crossref_primary_10_3390_ph15020151
crossref_primary_10_1039_D4AY00821A
crossref_primary_10_3390_pharmaceutics15020369
crossref_primary_10_3390_cancers15030707
crossref_primary_10_1186_s12876_025_03665_w
crossref_primary_10_3390_diseases11010049
crossref_primary_10_1016_j_biopha_2023_116030
crossref_primary_10_1016_j_jare_2022_08_018
crossref_primary_10_1007_s43440_024_00662_w
crossref_primary_10_3390_cancers15194787
crossref_primary_10_3390_ijms25042152
crossref_primary_10_1016_j_biopha_2023_115741
crossref_primary_10_1007_s12032_024_02591_3
crossref_primary_10_3390_genes15070953
crossref_primary_10_2139_ssrn_4118479
crossref_primary_10_3390_biomedicines12030698
crossref_primary_10_3390_cancers13225869
crossref_primary_10_3389_fonc_2023_1132177
crossref_primary_10_1016_j_ydbio_2024_12_007
crossref_primary_10_1016_j_aquatox_2024_106935
crossref_primary_10_3390_cimb45040218
crossref_primary_10_1016_j_metabol_2024_155794
crossref_primary_10_1021_acsami_2c02354
crossref_primary_10_1016_j_critrevonc_2024_104536
crossref_primary_10_1186_s12935_023_02914_w
crossref_primary_10_1016_j_drudis_2023_103684
crossref_primary_10_2174_1871520623666230824095226
crossref_primary_10_1016_j_adcanc_2022_100065
crossref_primary_10_3390_ani13111868
crossref_primary_10_3390_life12111890
crossref_primary_10_3390_nu14224792
crossref_primary_10_1016_j_canlet_2024_217046
crossref_primary_10_1038_s41598_024_53252_4
crossref_primary_10_3389_fphar_2024_1469392
crossref_primary_10_3390_jcdd11090296
crossref_primary_10_1016_j_canep_2024_102573
crossref_primary_10_3389_fcvm_2023_1133315
crossref_primary_10_3897_pharmacia_72_e138515
crossref_primary_10_3390_cancers14143500
crossref_primary_10_3389_fonc_2025_1450602
crossref_primary_10_1016_j_bbcan_2022_188756
crossref_primary_10_1016_j_adcanc_2023_100110
crossref_primary_10_1016_j_jconrel_2024_10_013
crossref_primary_10_1016_j_dsx_2023_102896
crossref_primary_10_1097_MD_0000000000037421
crossref_primary_10_1002_cam4_70342
crossref_primary_10_3390_ijms251810177
crossref_primary_10_1016_j_cbpc_2024_109905
crossref_primary_10_3389_fonc_2024_1435480
crossref_primary_10_1097_MAO_0000000000004469
crossref_primary_10_1038_s41598_025_87389_7
crossref_primary_10_2174_0929867330666230701000400
crossref_primary_10_1002_cam4_6826
crossref_primary_10_1152_ajpendo_00359_2023
crossref_primary_10_1038_s41569_022_00717_6
crossref_primary_10_3390_antiox13060679
crossref_primary_10_1186_s40360_024_00746_6
crossref_primary_10_1186_s12935_023_03138_8
crossref_primary_10_1038_s43018_022_00473_z
crossref_primary_10_1208_s12249_024_02957_w
crossref_primary_10_3390_biology13060455
crossref_primary_10_1039_D4OB01264J
crossref_primary_10_3390_ijms222413309
crossref_primary_10_3389_fonc_2023_1256747
crossref_primary_10_1016_j_drudis_2025_104308
crossref_primary_10_1038_s41591_024_02848_4
crossref_primary_10_1186_s12944_024_02261_3
crossref_primary_10_1111_jdv_19820
crossref_primary_10_3390_ijms241311206
crossref_primary_10_1007_s13225_023_00520_9
crossref_primary_10_2174_0115680096273730231206054104
crossref_primary_10_3389_fimmu_2024_1429523
crossref_primary_10_1016_j_ajps_2022_06_002
crossref_primary_10_1186_s12964_024_01649_z
crossref_primary_10_3389_fendo_2023_1134154
crossref_primary_10_1097_GH9_0000000000000461
crossref_primary_10_1186_s40001_024_01822_7
crossref_primary_10_3892_ijo_2022_5383
crossref_primary_10_1126_sciadv_adj7706
crossref_primary_10_1002_smll_202305708
crossref_primary_10_1158_1940_6207_CAPR_23_0423
crossref_primary_10_3390_ph15101211
crossref_primary_10_1007_s11095_024_03811_1
crossref_primary_10_1038_s41397_024_00346_x
crossref_primary_10_3389_fonc_2023_1150332
crossref_primary_10_1039_D4NA00808A
crossref_primary_10_3390_cancers15030886
crossref_primary_10_1016_j_ejcskn_2024_100017
crossref_primary_10_3390_ijms25105288
crossref_primary_10_1002_mco2_528
crossref_primary_10_3389_fmolb_2023_1160415
crossref_primary_10_1007_s44337_024_00012_y
crossref_primary_10_1158_1940_6207_CAPR_22_0420
crossref_primary_10_1186_s12944_023_01868_2
crossref_primary_10_61186_ijrr_22_2_505
crossref_primary_10_1158_2767_9764_CRC_23_0549
crossref_primary_10_1016_j_molmet_2024_102085
crossref_primary_10_1080_14737140_2024_2343338
crossref_primary_10_1172_jci_insight_161940
crossref_primary_10_1016_j_neuint_2023_105501
crossref_primary_10_1007_s00277_022_04802_1
crossref_primary_10_3342_kjorl_hns_2023_00731
crossref_primary_10_1021_acsptsci_4c00679
crossref_primary_10_3390_ijms26020535
crossref_primary_10_2147_BCTT_S336712
crossref_primary_10_1016_j_critrevonc_2024_104349
crossref_primary_10_1016_j_neo_2025_101154
crossref_primary_10_3390_ijms25010640
crossref_primary_10_3390_biomedicines11082247
crossref_primary_10_1158_2767_9764_CRC_24_0191
crossref_primary_10_1007_s10620_025_08935_x
crossref_primary_10_3892_ol_2024_14363
crossref_primary_10_1007_s00432_023_05102_5
crossref_primary_10_3390_immuno2020021
crossref_primary_10_1016_j_ccell_2023_04_016
crossref_primary_10_1016_j_onano_2023_100134
Cites_doi 10.1016/j.ejphar.2011.09.031
10.1016/j.cyto.2011.01.005
10.1016/j.tips.2017.05.002
10.1038/cddis.2013.44
10.1016/j.lungcan.2018.10.022
10.1038/nature14344
10.1016/j.ccell.2017.10.003
10.1016/S0165-6147(97)01147-4
10.3390/cancers12030671
10.1016/j.juro.2011.03.004
10.1016/j.jss.2011.06.037
10.1038/s41388-021-01874-7
10.1200/JCO.2016.69.2319
10.1111/jcmm.14879
10.1194/jlr.M800657-JLR200
10.1200/JCO.2016.66.8822
10.1016/j.cbi.2018.04.005
10.1016/j.bcp.2016.02.017
10.4143/crt.2020.1024
10.1097/MPH.0b013e318059c220
10.1016/j.bbalip.2008.04.006
10.1186/s13046-020-01723-7
10.5507/bp.2007.052
10.1371/journal.pone.0189233
10.1186/s40199-015-0121-x
10.1152/ajpendo.90926.2008
10.1042/BSR20170340
10.3389/fphar.2013.00119
10.1016/j.cell.2016.08.003
10.1016/j.canep.2013.10.010
10.1158/1078-0432.CCR-12-0489
10.1016/S0306-4522(02)00712-1
10.1016/j.healthpol.2010.12.002
10.1007/s10549-009-0507-x
10.1210/en.2003-0098
10.1016/j.freeradbiomed.2018.03.001
10.1038/s41586-019-1707-0
10.18632/oncotarget.6304
10.1097/EDE.0000000000000189
10.1016/j.cellsig.2008.04.012
10.5009/gnl15195
10.1038/s41418-017-0012-4
10.1158/1078-0432.CCR-17-2923
10.1038/nrc2013
10.1016/0005-2760(95)00051-D
10.3390/cancers12082055
10.1016/S0092-8674(00)80213-5
10.1016/j.intimp.2013.06.001
10.1097/01.mph.0000141348.62532.73
10.1161/01.ATV.0000200082.58536.e1
10.1038/s41586-019-0987-8
10.1016/j.phrs.2011.08.003
10.1136/gut.2011.237495
10.1038/nri3561
10.18632/oncotarget.8694
10.1016/j.tips.2013.06.005
10.1158/1078-0432.CCR-19-2853
10.1158/1078-0432.CCR-20-1967
10.1016/j.biopha.2016.12.105
10.1002/ijc.30526
10.1007/s10654-016-0145-7
10.1111/jcmm.15389
10.1002/ijc.33333
10.1007/s10654-019-00565-8
10.1111/bcpt.13320
10.1002/pds.1970
10.1371/journal.pone.0171137
10.1097/00008390-200504000-00001
10.1016/j.canlet.2018.05.025
10.1016/j.arr.2019.100962
10.1111/jcmm.13974
10.1016/j.biopha.2019.108892
10.1194/jlr.M034371
10.1016/j.cell.2019.05.026
10.3109/00498254.2011.569773
10.3892/or.2016.4631
10.1038/bjc.2012.138
10.18632/aging.101974
10.1016/j.bbamcr.2018.03.002
10.1038/cddis.2013.103
10.3389/fonc.2019.01032
10.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2
10.1016/j.ejca.2020.10.031
10.1136/bmj.292.6520.580
10.1038/s41556-018-0178-0
10.1016/j.dld.2020.01.008
10.1016/j.tcb.2014.09.001
10.1124/jpet.110.174870
10.1038/ncb2936
10.1038/s41598-018-35103-1
10.1111/aogs.13069
10.1038/srep25082
10.1016/j.bbalip.2013.03.003
10.1111/bjh.16635
10.1200/JCO.2016.68.3482
10.1124/jpet.110.174573
10.1111/eci.13388
10.1677/JOE-09-0271
10.1073/pnas.1912700116
10.7150/ijbs.42965
10.1016/j.cell.2012.03.042
10.1038/s41586-019-1705-2
10.1002/pros.21401
10.1007/s00280-008-0830-7
10.1038/343425a0
10.2147/OTT.S237693
10.1038/nrd2221
10.1111/1751-2980.12576
10.1016/j.ejca.2010.07.036
10.1038/nature18590
10.1371/journal.pone.0207858
10.1016/j.cmet.2005.04.006
10.1038/sj.onc.1209117
10.1080/10409238.2018.1458070
10.4143/crt.2020.430
10.1186/s12943-018-0900-3
10.1158/1078-0432.CCR-12-3172
10.3390/ijms151120607
10.1084/jem.20160392
10.1007/s00066-018-1347-6
10.1080/15384101.2019.1676581
10.1074/jbc.M505268200
10.1016/j.cmet.2019.04.002
10.18632/oncotarget.5749
10.1016/j.bbamcr.2014.02.002
10.1038/358167a0
10.1111/cas.14312
10.1158/1078-0432.CCR-20-1960
10.1016/j.ejphar.2011.10.044
10.1053/j.gastro.2017.05.011
10.1016/j.critrevonc.2014.08.002
10.1038/ncomms14128
10.1038/s41420-020-0252-9
10.1016/j.cell.2011.12.017
10.1007/s13277-015-3551-7
10.1593/neo.07727
10.1093/carcin/bgx018
10.1002/path.1700130103
10.1097/COC.0000000000000433
10.1158/1940-6207.CAPR-09-0059
10.1016/S0022-2275(20)30028-6
10.1016/j.ctrv.2016.11.009
10.1038/s41419-021-03389-1
10.1038/onc.2017.11
10.1080/01913123.2018.1522406
10.1016/j.drup.2016.02.001
10.1002/ijc.30738
10.1007/s11033-019-05019-8
10.1093/jnci/djr291
10.1002/pros.22758
10.1111/febs.15069
10.3390/cancers11070994
10.1016/j.tibs.2016.10.004
10.1186/s40170-018-0187-2
10.7150/jca.19100
10.1177/1010428317734947
10.1038/s41556-018-0042-2
10.1172/JCI0215593
10.1038/s41422-019-0164-5
10.1158/1940-6207.CAPR-20-0123
10.1016/j.bbcan.2020.188351
10.1016/j.trecan.2020.11.008
10.1016/j.phrs.2020.104919
10.3892/ijo.2017.4071
10.1038/cdd.2015.158
10.1038/nature15514
10.1007/s12094-018-1992-3
10.1158/1055-9965.EPI-15-0052
10.1016/j.bbrc.2007.12.166
10.1194/jlr.R800054-JLR200
10.1042/bst0230161
10.1590/1519-6984.11914
10.1038/srep44841
10.1210/clinem/dgaa877
10.3892/ol.2016.4569
10.3109/13880209.2016.1141221
10.1038/nrc.2016.76
10.1093/carcin/22.8.1139
10.1054/bjoc.2000.1716
10.1038/srep19435
10.3389/fonc.2018.00394
10.1093/aje/kwn141
10.4149/neo_2013_032
10.1016/j.mcna.2017.03.001
10.3390/cancers12061410
10.3892/ol.2020.12183
10.4274/balkanmedj.2017.0604
10.1038/cr.2015.139
10.1016/j.tcb.2017.05.005
10.1097/CAD.0000000000000885
10.1002/ijc.23593
10.4161/auto.2.2.2460
10.3389/fphar.2020.574068
10.2147/CMAR.S212643
10.1158/0008-5472.CAN-19-0644
10.1016/j.canlet.2020.05.005
10.1016/j.tcm.2004.08.003
10.18632/oncotarget.14868
10.4161/cbt.12.8.15978
10.2174/138955708784534436
10.1038/s41598-020-57707-2
10.1002/jcb.27544
10.1038/nrm.2015.11
10.1016/j.stemcr.2017.04.025
10.1172/JCI142616
10.1371/journal.pone.0045354
10.1007/s10549-009-0594-8
10.1016/j.canlet.2014.01.013
10.1016/j.jsps.2017.12.012
10.2147/CMAR.S247876
10.1016/j.ygyno.2019.05.022
10.1002/hed.25152
10.1126/science.290.5497.1721
10.3390/pharmaceutics12070597
10.1158/0008-5472.CAN-10-1626
10.1182/blood.V63.5.1186.1186
10.1038/s41586-020-2623-z
10.1038/bjc.2016.149
10.1056/NEJMoa1201735
10.1161/JAHA.119.018393
10.1016/j.cell.2011.02.013
10.1016/j.steroids.2018.12.003
10.1016/j.ejphar.2015.09.004
10.1016/j.atherosclerosis.2019.11.033
10.1038/nature22393
10.3322/caac.21660
10.1158/1055-9965.EPI-07-0531
10.1002/pros.22671
10.1002/(SICI)1097-0215(19991008)83:2<162::AID-IJC3>3.0.CO;2-W
10.1016/j.ejca.2014.08.005
10.1186/s12967-015-0486-0
10.1038/nature15541
10.1016/j.canlet.2006.10.009
10.1016/j.ebiom.2017.04.017
10.1186/s13046-016-0303-5
10.1172/JCI0216390
10.1111/j.1572-0241.2007.01773.x
10.1016/j.it.2011.02.002
10.18632/oncotarget.12694
10.1016/j.immuni.2013.07.017
10.1038/s41391-020-0221-7
10.1016/j.jhep.2019.04.021
10.1038/nrc2795
10.1007/s10495-011-0649-2
10.1038/nature23007
10.7150/thno.27246
10.3389/fonc.2020.00499
10.2174/156800905774932824
10.1158/1535-7163.MCT-16-0499
10.1016/j.chembiol.2015.11.016
10.1007/s10549-007-9683-8
10.1002/1878-0261.12775
10.1016/j.ccr.2006.06.001
10.1016/j.clinre.2020.101588
10.1161/ATVBAHA.108.179564
10.1016/j.mib.2013.04.004
10.1007/s10549-017-4246-0
10.1038/s41422-018-0090-y
10.4103/0973-1482.146127
10.1016/j.febslet.2008.06.034
10.1126/science.aaf2154
10.1016/0955-0674(92)90133-W
10.1016/j.dld.2011.01.010
10.1007/s12253-018-0415-7
10.1158/0008-5472.CAN-19-0650
10.1158/1078-0432.CCR-15-2973
10.1136/jnnp-2019-320893
10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F
10.15430/JCP.2014.19.2.75
10.1371/journal.pone.0139289
10.4161/auto.5.7.9444
10.1016/j.jhep.2005.04.010
10.1093/jnci/djw275
10.1038/s41392-020-00280-x
10.1111/cas.14493
10.1158/1078-0432.CCR-14-3368
10.1371/journal.pone.0067993
10.1016/j.pharmthera.2017.10.017
10.1016/j.bbagen.2013.04.011
10.2147/OTT.S106906
10.18632/oncotarget.16903
10.1136/jitc-2020-001361
10.1371/journal.pone.0028813
10.1073/pnas.1917938117
10.1016/j.it.2017.01.003
10.1016/j.cellsig.2009.12.010
10.1200/JCO.2005.02.7045
10.1016/0300-9084(93)90132-C
10.1021/acscentsci.9b01063
10.1158/1078-0432.CCR-10-2525
10.1038/nrc3262
10.1158/2159-8290.CD-19-1500
10.1038/cddis.2016.472
10.1016/S0009-9120(02)00421-6
10.1186/s12885-020-07164-x
10.1038/s41388-021-01701-z
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13046-021-02041-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database



MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 33
ExternalDocumentID oai_doaj_org_article_9beb19ece1274720b402642059ffe964
PMC8306262
A672348241
34303383
10_1186_s13046_021_02041_2
Genre Journal Article
Review
GrantInformation_xml – fundername: Natural Science Foundation of Anhui Province
  grantid: 1908085MH282
– fundername: ;
  grantid: 1908085MH282
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c660t-bdb43c1caa5daffe49fa7bb1f306bc92f0c70e75a436a87ec3b385e912d1444b3
IEDL.DBID 7X7
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:26:16 EDT 2025
Thu Aug 21 18:24:15 EDT 2025
Fri Jul 11 04:02:02 EDT 2025
Fri Jul 25 03:36:54 EDT 2025
Tue Jun 17 21:21:26 EDT 2025
Tue Jun 10 20:35:26 EDT 2025
Thu May 22 21:21:53 EDT 2025
Mon Jul 21 05:40:25 EDT 2025
Thu Apr 24 23:12:02 EDT 2025
Tue Jul 01 02:26:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Drug repurposing
Tumor microenvironment
Synergistic antitumor
Statins
Mevalonate pathway
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c660t-bdb43c1caa5daffe49fa7bb1f306bc92f0c70e75a436a87ec3b385e912d1444b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-8011-2405
OpenAccessLink https://www.proquest.com/docview/2562465131?pq-origsite=%requestingapplication%
PMID 34303383
PQID 2562465131
PQPubID 105475
PageCount 33
ParticipantIDs doaj_primary_oai_doaj_org_article_9beb19ece1274720b402642059ffe964
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8306262
proquest_miscellaneous_2555334357
proquest_journals_2562465131
gale_infotracmisc_A672348241
gale_infotracacademiconefile_A672348241
gale_healthsolutions_A672348241
pubmed_primary_34303383
crossref_primary_10_1186_s13046_021_02041_2
crossref_citationtrail_10_1186_s13046_021_02041_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-24
PublicationDateYYYYMMDD 2021-07-24
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-24
  day: 24
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Alizadeh (2041_CR165) 2017; 7
A Udristioiu (2041_CR224) 2019; 115
S Dessì (2041_CR180) 1994; 73
N Ghosh-Choudhury (2041_CR80) 2010; 22
Q Du (2041_CR198) 2016; 105
T Alarcon Martinez (2041_CR72) 2018; 35
DN Brown (2041_CR145) 2016; 6
PA Nguyen (2041_CR304) 2020; 111
S Piccolo (2041_CR6) 2013; 19
S Wang (2041_CR98) 2020; 6
M Li (2041_CR162) 2020; 19
CP White (2041_CR179) 1909; 13
JL Jouve (2041_CR54) 2019; 71
M Thurnher (2041_CR149) 2013; 1831
M Mehibel (2041_CR125) 2018; 8
EHK Mok (2041_CR200) 2020; 12
G Gruenbacher (2041_CR140) 2015; 356
WJ Wang (2041_CR280) 2018; 19
JP Friedmann Angeli (2041_CR263) 2018; 127
T Kusama (2041_CR177) 2001; 61
L Jiang (2041_CR253) 2015; 520
MH Zaki (2041_CR269) 2011; 32
K Shimada (2041_CR265) 2016; 23
Z Mei (2041_CR58) 2017; 140
AR Wolfe (2041_CR287) 2016; 7
2041_CR28
X Qi (2041_CR109) 2013; 4
2041_CR315
DS Kazi (2041_CR13) 2017; 101
GP Risbridger (2041_CR189) 2010; 10
PW Voorneveld (2041_CR31) 2017; 153
LM Merlo (2041_CR284) 2006; 6
RE Gordon (2041_CR219) 2018; 24
M Wang (2041_CR143) 2016; 17
D Athavale (2041_CR208) 2018; 6
C Taccioli (2041_CR298) 2015; 6
SW Huang (2041_CR74) 2020; 24
Y Tu (2041_CR131) 2011; 670
Y Kobayashi (2041_CR104) 2015; 21
Y Wang (2041_CR276) 2017; 547
J Deng (2041_CR82) 2019; 11
U Khanzada (2041_CR106) 2006; 25
I Agalliu (2041_CR67) 2008; 168
PR Yang (2041_CR60) 2020; 12
MJ Rudling (2041_CR188) 1986; 292
O Ogunwobi (2041_CR117) 2008; 103
D Tang (2041_CR250) 2019; 29
C Denoyelle (2041_CR160) 2001; 22
Y Zhang (2041_CR303) 2019; 18
JW Wojtkowiak (2041_CR242) 2011; 337
A Belavgeni (2041_CR257) 2019; 116
N Kayagaki (2041_CR274) 2015; 526
T Docrat (2041_CR99) 2018; 287
P Saraon (2041_CR205) 2014; 74
AD Attie (2041_CR193) 2005; 1
TK Svendsen (2041_CR295) 2020; 126
G Fritz (2041_CR155) 2005; 27
S Bonovas (2041_CR65) 2005; 23
N Lebo (2041_CR46) 2018; 40
J Longo (2041_CR50) 2020; 23
K Sheikholeslami (2041_CR158) 2019; 11
K Tveten (2041_CR207) 2013; 54
D Fujiwara (2041_CR167) 2017; 39
S Hombach-Klonisch (2041_CR245) 2018; 184
MB Hu (2041_CR243) 2018; 42
MZ Jin (2041_CR285) 2020; 5
C Cardwell (2041_CR19) 2015; 26
V Narwal (2041_CR146) 2019; 143
D Fukumura (2041_CR291) 2001; 61
S Kawata (2041_CR55) 2001; 84
YC Castellanos-Esparza (2041_CR79) 2018; 52
H Jang (2041_CR94) 2016; 12
J Jang (2041_CR128) 2019; 46
S Galland (2041_CR108) 2020; 484
K Bersuker (2041_CR259) 2019; 575
Z Wang (2041_CR85) 2020; 26
S Shojaei (2041_CR112) 2020; 287
L Luput (2041_CR301) 2020; 111
P Bertolini (2041_CR308) 2004; 26
J Longo (2041_CR296) 2020; 26
JY Bae (2041_CR197) 2017; 8
M Narita (2041_CR230) 2009; 5
M Koyuturk (2041_CR73) 2007; 250
CF Yen (2041_CR184) 1995; 1257
M Hung (2041_CR35) 2017; 12
X Song (2041_CR110) 2014; 1843
WA Freed-Pastor (2041_CR172) 2012; 148
SC Gupta (2041_CR3) 2013; 34
Y Jiang (2041_CR203) 2019; 567
K Sheikholeslami (2041_CR111) 2019; 11
S Samarghandian (2041_CR222) 2003; 116
H Sung (2041_CR1) 2021; 71
JW Chung (2041_CR15) 2020; 91
JL Goldstein (2041_CR136) 1990; 343
H Jin (2041_CR286) 2019; 9
C Seliger (2041_CR40) 2018; 13
Y Chen (2041_CR186) 2001; 91
S Kochuparambil (2041_CR86) 2011; 336
D Wallach (2041_CR270) 2014; 14
C Chang (2041_CR26) 2011; 71
D Tamburrino (2041_CR62) 2020; 52
J Ding (2041_CR272) 2016; 535
A Ghaderi (2041_CR221) 2015; 23
E White (2041_CR228) 2012; 12
WT He (2041_CR273) 2015; 25
RA Aglietti (2041_CR279) 2017; 38
SJ Dixon (2041_CR248) 2012; 149
G Sorrentino (2041_CR7) 2014; 16
S Doll (2041_CR260) 2019; 575
2041_CR30
Y Yan (2041_CR246) 2016; 35
Z Lin (2041_CR77) 2017; 8
C Riganti (2041_CR153) 2008; 8
P Otruba (2041_CR294) 2007; 151
PMR Pereira (2041_CR302) 2020; 26
BA Hamelin (2041_CR10) 1998; 19
C Sperling (2041_CR43) 2017; 96
B Buranrat (2041_CR78) 2017; 14
L Galluzzi (2041_CR225) 2019; 177
GZ Qiu (2041_CR288) 2017; 38
C Jespersen (2041_CR24) 2014; 38
C Zhao (2041_CR209) 2010; 204
V Ivanov (2041_CR113) 2011; 16
PJ Casey (2041_CR154) 1995; 23
Q Zhang (2041_CR16) 2020; 16
WB Zhong (2041_CR176) 2003; 144
L Smyth (2041_CR39) 2020; 191
DG Menter (2041_CR12) 2011; 6
X Hong (2041_CR256) 2021; 11
F Bai (2041_CR75) 2019; 11
T Ahern (2041_CR20) 2011; 103
Y Qiu (2041_CR252) 2020; 159
2041_CR49
J Shi (2041_CR267) 2017; 42
Y Chen (2041_CR91) 2020; 12
Q Liu (2041_CR93) 2020; 13
Y Aachoui (2041_CR277) 2013; 16
Y Peng (2041_CR123) 2017; 8
X Ma (2041_CR116) 2019; 30
L Zhang (2041_CR127) 2019; 9
Z Jiao (2041_CR170) 2020; 117
N Ortiz (2041_CR92) 2020; 20
EA Collisson (2041_CR178) 2003; 2
U Vilimanovich (2041_CR239) 2015; 765
DP Bi (2041_CR214) 2016; 35
J Longo (2041_CR307) 2020; 14
Z Yang (2041_CR237) 2017; 19
M Misirkic (2041_CR238) 2012; 65
A Jeong (2041_CR139) 2018; 53
N Lee (2041_CR126) 2020; 24
M Araki (2041_CR236) 2012; 674
VAN Kraft (2041_CR261) 2020; 6
Y Li (2041_CR300) 2017; 8
G Helbig (2041_CR163) 2004; 57
Q Fan (2041_CR220) 2021; 40
X Wu (2041_CR96) 2017; 38
A Couttenier (2041_CR34) 2017; 12
J Lee (2041_CR118) 2016; 10
S Kim (2041_CR129) 2016; 54
Z Yang (2041_CR14) 2020; 57
A Majidi (2041_CR59) 2021; 148
N Hagiwara (2041_CR132) 2018; 431
P Yang (2041_CR29) 2020; 12
2041_CR174
A Cortellini (2041_CR305) 2020; 8
M Thurnher (2041_CR144) 2012; 18
W Kamel (2041_CR120) 2017; 16
M Feldt (2041_CR48) 2015; 13
MM Islam (2041_CR68) 2020; 12
JL Goldstein (2041_CR206) 2009; 29
MD Rybstein (2041_CR226) 2018; 20
RK Yadav (2041_CR234) 2014; 19
D Ribatti (2041_CR290) 2016; 7
G Sarrabayrouse (2041_CR168) 2007; 9
D Basuli (2041_CR258) 2017; 36
GH McGregor (2041_CR297) 2020; 80
D Cote (2041_CR42) 2019; 34
N Mohammadzadeh (2041_CR4) 2020; 50
F Iannelli (2041_CR299) 2020; 39
N Toepfer (2041_CR89) 2011; 12
KA Fernandez (2041_CR313) 2021; 131
H Abdel-Qadir (2041_CR314) 2021; 10
NA Iarrobino (2041_CR63) 2018; 41
B Zhou (2041_CR281) 2018; 28
ER Garwood (2041_CR47) 2010; 119
MS Brown (2041_CR191) 1997; 89
N Gueddari (2041_CR182) 1993; 75
H You (2041_CR101) 2016; 9
A Göbel (2041_CR137) 2020; 1873
Q Wang (2041_CR216) 2019; 23
A Zychlinsky (2041_CR268) 1992; 358
M Nayan (2041_CR44) 2017; 52
W Likus (2041_CR190) 2016; 25
M Brown (2041_CR88) 2012; 106
A Otahal (2041_CR105) 2020; 10
EH Allott (2041_CR23) 2020; 26
L Cantini (2041_CR69) 2021; 144
A Hoque (2041_CR90) 2008; 17
Y Zhu (2041_CR159) 2013; 4
K Kolanjiappan (2041_CR181) 2003; 36
H Liu (2041_CR107) 2013; 60
T Gehrke (2041_CR124) 2017; 51
A Ouvrier (2041_CR213) 2009; 50
JM Ubellacker (2041_CR255) 2020; 585
AJ McFarland (2041_CR293) 2014; 15
J Shi (2041_CR271) 2015; 526
I Kaymak (2041_CR169) 2020; 80
S Marnitz (2041_CR312) 2018; 194
L Yin (2041_CR171) 2020; 11
F Verdoodt (2041_CR33) 2017; 141
C Cardwell (2041_CR36) 2015; 24
Y Zhang (2041_CR133) 2019; 18
J Kim (2041_CR134) 2019; 154
PM Cruz (2041_CR147) 2013; 4
G Gruenbacher (2041_CR141) 2018; 8
O Abdel-Rahman (2041_CR27) 2019; 21
B Weichand (2041_CR199) 2017; 214
Y Shellman (2041_CR115) 2005; 15
G Daniil (2041_CR211) 2013; 8
PJ Rosch (2041_CR61) 2013; 368
P Trojan (2041_CR130) 2016; 76
N Tan (2041_CR22) 2011; 186
2041_CR138
N van Beek (2041_CR227) 2018; 1865
RL Carpenter (2041_CR218) 2012; 13
KR Knight (2041_CR311) 2017; 35
ST Kim (2041_CR51) 2014; 50
CM Kenific (2041_CR232) 2015; 25
M Araki (2041_CR235) 2008; 367
D Schaafsma (2041_CR152) 2008; 20
I Georgakopoulos-Soares (2041_CR173) 2020; 10
T Fukamachi (2041_CR292) 2013; 17
S Morgan (2041_CR2) 2011; 100
L Li (2041_CR32) 2021; 45
D Hanahan (2041_CR135) 2011; 144
D Wallach (2041_CR266) 2016; 352
SJ Cho (2041_CR166) 2008; 123
Y Shi (2041_CR244) 2012; 7
SB Kovacs (2041_CR278) 2017; 27
A Cordle (2041_CR151) 2005; 280
L Matusewicz (2041_CR17) 2015; 36
M Choi (2041_CR18) 2021; 53
PP Coradini (2041_CR309) 2007; 29
Y Ma (2041_CR231) 2013; 39
B Moosmann (2041_CR262) 2004; 14
M Moossavi (2041_CR196) 2018; 17
A Sutter (2041_CR97) 2005; 43
Y Xie (2041_CR251) 2016; 23
PA Konstantinopoulos (2041_CR150) 2007; 6
C Rogers (2041_CR275) 2017; 8
T Wang (2041_CR71) 2016; 7
K Xia (2041_CR102) 2018; 15
K Asakura (2041_CR241) 2011; 170
S Vitols (2041_CR187) 1984; 63
S Jin (2041_CR229) 2006; 2
F Geng (2041_CR202) 2016; 22
S Nielsen (2041_CR56) 2012; 367
X Zheng (2041_CR87) 2010; 3
DF Lum (2041_CR183) 1999; 83
K Howe (2041_CR8) 2011; 41
PJ Mullen (2041_CR142) 2016; 16
K Simons (2041_CR148) 2002; 110
K Sanfilippo (2041_CR45) 2016; 34
S Samarghandian (2041_CR223) 2017; 87
J Dulak (2041_CR9) 2005; 5
A Wang (2041_CR57) 2016; 115
Z Awan (2041_CR70) 2020; 12
B Liu (2041_CR64) 2017; 164
CJ Der (2041_CR156) 1991; 3
H Liu (2041_CR103) 2009; 63
L Galluzzi (2041_CR249) 2018; 25
K Simons (2041_CR195) 2000; 290
CJ Antalis (2041_CR204) 2010; 122
C Yen (2041_CR122) 2016; 6
MS Brown (2041_CR194) 2009; 50 Suppl
A Al-Qatati (2041_CR114) 2017; 14
AD Cox (2041_CR157) 1992; 4
LM Wu (2041_CR282) 2020; 293
MS Geybels (2041_CR66) 2013; 73
C Seliger (2041_CR41) 2016; 31
P Kubatka (2041_CR161) 2014; 92
JD Horton (2041_CR192) 2002; 109
JY Han (2041_CR53) 2011; 17
A Palazon (2041_CR289) 2017; 32
Y Zhang (2041_CR254) 2018; 20
A Göbel (2041_CR175) 2020; 20
IC Gelissen (2041_CR210) 2006; 26
PM Yang (2041_CR240) 2010; 70
P Huang (2041_CR217) 2016; 166
G Herrero-Martin (2041_CR81) 2008; 582
IR Konings (2041_CR52) 2010; 46
M Afzali (2041_CR76) 2016; 12
M Tsubaki (2041_CR121) 2011; 54
S Wang (2041_CR100) 2017; 8
ML Kwan (2041_CR21) 2008; 109
S Cho (2041_CR38) 2015; 10
M Alqudah (2041_CR83) 2018; 26
T Miller (2041_CR119) 2011; 43
L Tatidis (2041_CR185) 1997; 38
TY Chang (2041_CR201) 2009; 297
JM Jiménez-Vacas (2041_CR306) 2021; 106
P Coogan (2041_CR25) 2010; 19
MH Ung (2041_CR37) 2018; 126
VS Viswanathan (2041_CR264) 2017; 547
S Kato (2041_CR11) 2010; 14
A Chen (2041_CR283) 2021; 12
H Chang (2041_CR95) 2013; 1830
K Degenhardt (2041_CR233) 2006; 10
B Sheng (2041_CR247) 2020; 12
B Chen (2041_CR84) 2017; 37
I Lorenzi (2041_CR212) 2008; 1781
LL Kodach (2041_CR5) 2011; 60
C Su (2041_CR215) 2019; 18
T Hu (2041_CR164) 2020; 31
RD Frisina (2041_CR310) 2016; 34
References_xml – volume: 670
  start-page: 356
  year: 2011
  ident: 2041_CR131
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2011.09.031
– volume: 2
  start-page: 941
  issue: 10
  year: 2003
  ident: 2041_CR178
  publication-title: Mol Cancer Ther
– volume: 54
  start-page: 100
  issue: 1
  year: 2011
  ident: 2041_CR121
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2011.01.005
– volume: 61
  start-page: 4885
  issue: 12
  year: 2001
  ident: 2041_CR177
  publication-title: Cancer Res
– volume: 38
  start-page: 669
  issue: 8
  year: 2017
  ident: 2041_CR288
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2017.05.002
– volume: 4
  start-page: e518
  year: 2013
  ident: 2041_CR109
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2013.44
– volume: 126
  start-page: 89
  year: 2018
  ident: 2041_CR37
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.10.022
– volume: 520
  start-page: 57
  issue: 7545
  year: 2015
  ident: 2041_CR253
  publication-title: Nature
  doi: 10.1038/nature14344
– volume: 32
  start-page: 669
  issue: 5
  year: 2017
  ident: 2041_CR289
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.10.003
– volume: 19
  start-page: 26
  issue: 1
  year: 1998
  ident: 2041_CR10
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/S0165-6147(97)01147-4
– volume: 12
  start-page: 671
  issue: 3
  year: 2020
  ident: 2041_CR68
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12030671
– volume: 186
  start-page: 86
  issue: 1
  year: 2011
  ident: 2041_CR22
  publication-title: J Urol
  doi: 10.1016/j.juro.2011.03.004
– volume: 170
  start-page: e197
  issue: 2
  year: 2011
  ident: 2041_CR241
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2011.06.037
– ident: 2041_CR315
  doi: 10.1038/s41388-021-01874-7
– volume: 19
  start-page: 2861
  issue: 4
  year: 2020
  ident: 2041_CR162
  publication-title: Exp Ther Med
– volume: 35
  start-page: 440
  issue: 4
  year: 2017
  ident: 2041_CR311
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.69.2319
– volume: 24
  start-page: 1822
  issue: 2
  year: 2020
  ident: 2041_CR74
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.14879
– volume: 50
  start-page: 1766
  issue: 9
  year: 2009
  ident: 2041_CR213
  publication-title: J Lipid Res
  doi: 10.1194/jlr.M800657-JLR200
– volume: 34
  start-page: 2712
  issue: 23
  year: 2016
  ident: 2041_CR310
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.66.8822
– volume: 287
  start-page: 32
  year: 2018
  ident: 2041_CR99
  publication-title: Chem Biol Interact
  doi: 10.1016/j.cbi.2018.04.005
– volume: 105
  start-page: 42
  year: 2016
  ident: 2041_CR198
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2016.02.017
– ident: 2041_CR49
  doi: 10.4143/crt.2020.1024
– volume: 29
  start-page: 355
  issue: 6
  year: 2007
  ident: 2041_CR309
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0b013e318059c220
– volume: 1781
  start-page: 306
  issue: 6–7
  year: 2008
  ident: 2041_CR212
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbalip.2008.04.006
– volume: 39
  start-page: 213
  issue: 1
  year: 2020
  ident: 2041_CR299
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01723-7
– volume: 151
  start-page: 307
  issue: 2
  year: 2007
  ident: 2041_CR294
  publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  doi: 10.5507/bp.2007.052
– volume: 12
  start-page: e0189233
  issue: 12
  year: 2017
  ident: 2041_CR34
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0189233
– volume: 23
  start-page: 39
  issue: 1
  year: 2015
  ident: 2041_CR221
  publication-title: Daru
  doi: 10.1186/s40199-015-0121-x
– volume: 297
  start-page: E1
  issue: 1
  year: 2009
  ident: 2041_CR201
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.90926.2008
– volume: 37
  start-page: BSR20170340
  issue: 4
  year: 2017
  ident: 2041_CR84
  publication-title: Biosci Rep
  doi: 10.1042/BSR20170340
– volume: 3
  start-page: 331
  issue: 9
  year: 1991
  ident: 2041_CR156
  publication-title: Cancer Cells
– volume: 4
  start-page: 119
  year: 2013
  ident: 2041_CR147
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2013.00119
– volume: 166
  start-page: 1176
  issue: 5
  year: 2016
  ident: 2041_CR217
  publication-title: Cell
  doi: 10.1016/j.cell.2016.08.003
– volume: 38
  start-page: 42
  issue: 1
  year: 2014
  ident: 2041_CR24
  publication-title: Cancer Epidemiol
  doi: 10.1016/j.canep.2013.10.010
– volume: 18
  start-page: 3524
  issue: 13
  year: 2012
  ident: 2041_CR144
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-0489
– volume: 27
  start-page: 1401
  issue: 5
  year: 2005
  ident: 2041_CR155
  publication-title: Int J Oncol
– volume: 116
  start-page: 519
  issue: 2
  year: 2003
  ident: 2041_CR222
  publication-title: Neuroscience
  doi: 10.1016/S0306-4522(02)00712-1
– volume: 100
  start-page: 4
  issue: 1
  year: 2011
  ident: 2041_CR2
  publication-title: Health Policy
  doi: 10.1016/j.healthpol.2010.12.002
– volume: 119
  start-page: 137
  issue: 1
  year: 2010
  ident: 2041_CR47
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-009-0507-x
– volume: 144
  start-page: 3852
  issue: 9
  year: 2003
  ident: 2041_CR176
  publication-title: Endocrinology
  doi: 10.1210/en.2003-0098
– volume: 127
  start-page: 153
  year: 2018
  ident: 2041_CR263
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2018.03.001
– volume: 575
  start-page: 693
  issue: 7784
  year: 2019
  ident: 2041_CR260
  publication-title: Nature
  doi: 10.1038/s41586-019-1707-0
– volume: 7
  start-page: 2532
  issue: 3
  year: 2016
  ident: 2041_CR71
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6304
– volume: 26
  start-page: 68
  issue: 1
  year: 2015
  ident: 2041_CR19
  publication-title: Epidemiology
  doi: 10.1097/EDE.0000000000000189
– volume: 20
  start-page: 1705
  issue: 10
  year: 2008
  ident: 2041_CR152
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2008.04.012
– volume: 10
  start-page: 310
  issue: 2
  year: 2016
  ident: 2041_CR118
  publication-title: Gut Liver
  doi: 10.5009/gnl15195
– volume: 25
  start-page: 486
  issue: 3
  year: 2018
  ident: 2041_CR249
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-017-0012-4
– volume: 24
  start-page: 1375
  issue: 6
  year: 2018
  ident: 2041_CR219
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2923
– volume: 6
  start-page: 924
  issue: 12
  year: 2006
  ident: 2041_CR284
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2013
– volume: 1257
  start-page: 47
  issue: 1
  year: 1995
  ident: 2041_CR184
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0005-2760(95)00051-D
– volume: 12
  start-page: 2055
  issue: 8
  year: 2020
  ident: 2041_CR29
  publication-title: Cancers
  doi: 10.3390/cancers12082055
– volume: 89
  start-page: 331
  issue: 3
  year: 1997
  ident: 2041_CR191
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80213-5
– volume: 17
  start-page: 148
  issue: 1
  year: 2013
  ident: 2041_CR292
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2013.06.001
– volume: 26
  start-page: 649
  issue: 10
  year: 2004
  ident: 2041_CR308
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/01.mph.0000141348.62532.73
– volume: 26
  start-page: 534
  issue: 3
  year: 2006
  ident: 2041_CR210
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000200082.58536.e1
– volume: 567
  start-page: 257
  issue: 7747
  year: 2019
  ident: 2041_CR203
  publication-title: Nature
  doi: 10.1038/s41586-019-0987-8
– volume: 65
  start-page: 111
  issue: 1
  year: 2012
  ident: 2041_CR238
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2011.08.003
– volume: 60
  start-page: 1544
  issue: 11
  year: 2011
  ident: 2041_CR5
  publication-title: Gut
  doi: 10.1136/gut.2011.237495
– volume: 14
  start-page: 51
  issue: 1
  year: 2014
  ident: 2041_CR270
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3561
– volume: 7
  start-page: 46668
  issue: 29
  year: 2016
  ident: 2041_CR290
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8694
– volume: 34
  start-page: 508
  issue: 9
  year: 2013
  ident: 2041_CR3
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2013.06.005
– volume: 26
  start-page: 1086
  issue: 5
  year: 2020
  ident: 2041_CR23
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-2853
– volume: 26
  start-page: 5791
  issue: 22
  year: 2020
  ident: 2041_CR296
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1967
– volume: 87
  start-page: 223
  year: 2017
  ident: 2041_CR223
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2016.12.105
– volume: 140
  start-page: 1068
  issue: 5
  year: 2017
  ident: 2041_CR58
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30526
– volume: 31
  start-page: 947
  issue: 9
  year: 2016
  ident: 2041_CR41
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-016-0145-7
– volume: 24
  start-page: 7055
  issue: 12
  year: 2020
  ident: 2041_CR126
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.15389
– volume: 148
  start-page: 1608
  issue: 7
  year: 2021
  ident: 2041_CR59
  publication-title: Int J Cancer
  doi: 10.1002/ijc.33333
– volume: 34
  start-page: 997
  issue: 11
  year: 2019
  ident: 2041_CR42
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-019-00565-8
– volume: 126
  start-page: 203
  issue: 3
  year: 2020
  ident: 2041_CR295
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/bcpt.13320
– volume: 19
  start-page: 752
  issue: 7
  year: 2010
  ident: 2041_CR25
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.1970
– volume: 12
  start-page: e0171137
  issue: 2
  year: 2017
  ident: 2041_CR35
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0171137
– volume: 15
  start-page: 83
  issue: 2
  year: 2005
  ident: 2041_CR115
  publication-title: Melanoma Res
  doi: 10.1097/00008390-200504000-00001
– volume: 431
  start-page: 182
  year: 2018
  ident: 2041_CR132
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.05.025
– volume: 57
  start-page: 100962
  year: 2020
  ident: 2041_CR14
  publication-title: Ageing Res Rev
  doi: 10.1016/j.arr.2019.100962
– volume: 52
  start-page: 1246
  issue: 4
  year: 2018
  ident: 2041_CR79
  publication-title: Int J Oncol
– volume: 23
  start-page: 789
  issue: 2
  year: 2019
  ident: 2041_CR216
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.13974
– volume: 115
  start-page: 108892
  year: 2019
  ident: 2041_CR224
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.108892
– volume: 54
  start-page: 1560
  issue: 6
  year: 2013
  ident: 2041_CR207
  publication-title: J Lipid Res
  doi: 10.1194/jlr.M034371
– volume: 12
  start-page: 2055
  issue: 8
  year: 2020
  ident: 2041_CR60
  publication-title: Cancers (Basel).
  doi: 10.3390/cancers12082055
– volume: 177
  start-page: 1682
  issue: 7
  year: 2019
  ident: 2041_CR225
  publication-title: Cell
  doi: 10.1016/j.cell.2019.05.026
– volume: 41
  start-page: 519
  issue: 7
  year: 2011
  ident: 2041_CR8
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2011.569773
– volume: 35
  start-page: 2873
  issue: 5
  year: 2016
  ident: 2041_CR214
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4631
– volume: 13
  start-page: 105
  issue: 69
  year: 2012
  ident: 2041_CR218
  publication-title: Discov Med
– volume: 106
  start-page: 1689
  issue: 10
  year: 2012
  ident: 2041_CR88
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.138
– volume: 11
  start-page: 3198
  issue: 10
  year: 2019
  ident: 2041_CR75
  publication-title: Aging
  doi: 10.18632/aging.101974
– volume: 1865
  start-page: 803
  issue: 5
  year: 2018
  ident: 2041_CR227
  publication-title: Biochim Biophys Acta Mol Cell Res
  doi: 10.1016/j.bbamcr.2018.03.002
– volume: 4
  start-page: e568
  issue: 4
  year: 2013
  ident: 2041_CR159
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2013.103
– volume: 9
  start-page: 1032
  year: 2019
  ident: 2041_CR127
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.01032
– volume: 91
  start-page: 41
  issue: 1
  year: 2001
  ident: 2041_CR186
  publication-title: Int J Cancer
  doi: 10.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2
– volume: 144
  start-page: 41
  year: 2021
  ident: 2041_CR69
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2020.10.031
– volume: 292
  start-page: 580
  issue: 6520
  year: 1986
  ident: 2041_CR188
  publication-title: Br Med J (Clin Res Ed)
  doi: 10.1136/bmj.292.6520.580
– volume: 20
  start-page: 1181
  issue: 10
  year: 2018
  ident: 2041_CR254
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0178-0
– volume: 52
  start-page: 392
  issue: 4
  year: 2020
  ident: 2041_CR62
  publication-title: Dig Liver Dis
  doi: 10.1016/j.dld.2020.01.008
– volume: 25
  start-page: 37
  issue: 1
  year: 2015
  ident: 2041_CR232
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2014.09.001
– volume: 336
  start-page: 496
  issue: 2
  year: 2011
  ident: 2041_CR86
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.174870
– volume: 16
  start-page: 357
  issue: 4
  year: 2014
  ident: 2041_CR7
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2936
– volume: 8
  start-page: 16804
  issue: 1
  year: 2018
  ident: 2041_CR125
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-35103-1
– volume: 96
  start-page: 144
  issue: 2
  year: 2017
  ident: 2041_CR43
  publication-title: Acta Obstet Gynecol Scand
  doi: 10.1111/aogs.13069
– volume: 6
  start-page: 25082
  year: 2016
  ident: 2041_CR122
  publication-title: Sci Rep
  doi: 10.1038/srep25082
– volume: 1831
  start-page: 1009
  issue: 6
  year: 2013
  ident: 2041_CR149
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbalip.2013.03.003
– volume: 191
  start-page: 396
  issue: 3
  year: 2020
  ident: 2041_CR39
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16635
– volume: 34
  start-page: 4008
  issue: 33
  year: 2016
  ident: 2041_CR45
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.68.3482
– volume: 337
  start-page: 65
  issue: 1
  year: 2011
  ident: 2041_CR242
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.174573
– volume: 50
  start-page: e13388
  issue: 12
  year: 2020
  ident: 2041_CR4
  publication-title: Eur J Clin Invest
  doi: 10.1111/eci.13388
– volume: 204
  start-page: 233
  issue: 3
  year: 2010
  ident: 2041_CR209
  publication-title: J Endocrinol
  doi: 10.1677/JOE-09-0271
– volume: 116
  start-page: 22269
  issue: 44
  year: 2019
  ident: 2041_CR257
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1912700116
– volume: 16
  start-page: 2704
  issue: 14
  year: 2020
  ident: 2041_CR16
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.42965
– volume: 149
  start-page: 1060
  issue: 5
  year: 2012
  ident: 2041_CR248
  publication-title: Cell
  doi: 10.1016/j.cell.2012.03.042
– volume: 575
  start-page: 688
  issue: 7784
  year: 2019
  ident: 2041_CR259
  publication-title: Nature
  doi: 10.1038/s41586-019-1705-2
– volume: 71
  start-page: 1818
  issue: 16
  year: 2011
  ident: 2041_CR26
  publication-title: Prostate
  doi: 10.1002/pros.21401
– volume: 63
  start-page: 997
  issue: 6
  year: 2009
  ident: 2041_CR103
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-008-0830-7
– volume: 343
  start-page: 425
  issue: 6257
  year: 1990
  ident: 2041_CR136
  publication-title: Nature
  doi: 10.1038/343425a0
– volume: 13
  start-page: 2057
  year: 2020
  ident: 2041_CR93
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S237693
– volume: 6
  start-page: 541
  issue: 7
  year: 2007
  ident: 2041_CR150
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2221
– volume: 19
  start-page: 74
  issue: 2
  year: 2018
  ident: 2041_CR280
  publication-title: J Dig Dis
  doi: 10.1111/1751-2980.12576
– volume: 46
  start-page: 3200
  issue: 18
  year: 2010
  ident: 2041_CR52
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2010.07.036
– volume: 535
  start-page: 111
  issue: 7610
  year: 2016
  ident: 2041_CR272
  publication-title: Nature
  doi: 10.1038/nature18590
– volume: 13
  start-page: e0207858
  issue: 12
  year: 2018
  ident: 2041_CR40
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0207858
– volume: 1
  start-page: 290
  issue: 5
  year: 2005
  ident: 2041_CR193
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2005.04.006
– volume: 25
  start-page: 877
  issue: 6
  year: 2006
  ident: 2041_CR106
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209117
– volume: 53
  start-page: 279
  issue: 3
  year: 2018
  ident: 2041_CR139
  publication-title: Crit Rev Biochem Mol Biol
  doi: 10.1080/10409238.2018.1458070
– volume: 53
  start-page: 65
  issue: 1
  year: 2021
  ident: 2041_CR18
  publication-title: Cancer Res Treat
  doi: 10.4143/crt.2020.430
– volume: 17
  start-page: 158
  issue: 1
  year: 2018
  ident: 2041_CR196
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0900-3
– volume: 19
  start-page: 4925
  issue: 18
  year: 2013
  ident: 2041_CR6
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-3172
– volume: 15
  start-page: 20607
  issue: 11
  year: 2014
  ident: 2041_CR293
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms151120607
– volume: 214
  start-page: 2695
  issue: 9
  year: 2017
  ident: 2041_CR199
  publication-title: J Exp Med
  doi: 10.1084/jem.20160392
– volume: 194
  start-page: 1039
  issue: 11
  year: 2018
  ident: 2041_CR312
  publication-title: Strahlenther Onkol
  doi: 10.1007/s00066-018-1347-6
– volume: 18
  start-page: 3337
  issue: 23
  year: 2019
  ident: 2041_CR303
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2019.1676581
– volume: 280
  start-page: 34202
  issue: 40
  year: 2005
  ident: 2041_CR151
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M505268200
– volume: 30
  start-page: 143
  issue: 1
  year: 2019
  ident: 2041_CR116
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.04.002
– volume: 6
  start-page: 38854
  issue: 36
  year: 2015
  ident: 2041_CR298
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5749
– volume: 1843
  start-page: 894
  issue: 5
  year: 2014
  ident: 2041_CR110
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamcr.2014.02.002
– volume: 358
  start-page: 167
  issue: 6382
  year: 1992
  ident: 2041_CR268
  publication-title: Nature
  doi: 10.1038/358167a0
– volume: 111
  start-page: 1344
  issue: 4
  year: 2020
  ident: 2041_CR301
  publication-title: Cancer Sci
  doi: 10.1111/cas.14312
– volume: 26
  start-page: 6215
  issue: 23
  year: 2020
  ident: 2041_CR302
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1960
– volume: 674
  start-page: 95
  issue: 2–3
  year: 2012
  ident: 2041_CR236
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2011.10.044
– volume: 153
  start-page: 470
  issue: 2
  year: 2017
  ident: 2041_CR31
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2017.05.011
– volume: 92
  start-page: 296
  issue: 3
  year: 2014
  ident: 2041_CR161
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2014.08.002
– volume: 8
  start-page: 14128
  year: 2017
  ident: 2041_CR275
  publication-title: Nat Commun
  doi: 10.1038/ncomms14128
– volume: 15
  start-page: 4344
  issue: 4
  year: 2018
  ident: 2041_CR102
  publication-title: Oncol Lett
– volume: 6
  start-page: 17
  year: 2020
  ident: 2041_CR98
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-020-0252-9
– volume: 148
  start-page: 244
  issue: 1–2
  year: 2012
  ident: 2041_CR172
  publication-title: Cell
  doi: 10.1016/j.cell.2011.12.017
– volume: 36
  start-page: 4889
  issue: 7
  year: 2015
  ident: 2041_CR17
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3551-7
– volume: 9
  start-page: 1078
  issue: 12
  year: 2007
  ident: 2041_CR168
  publication-title: Neoplasia
  doi: 10.1593/neo.07727
– volume: 38
  start-page: 455
  issue: 4
  year: 2017
  ident: 2041_CR96
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgx018
– volume: 13
  start-page: 3
  issue: 1
  year: 1909
  ident: 2041_CR179
  publication-title: J Pathol Bacteriol
  doi: 10.1002/path.1700130103
– volume: 41
  start-page: 1125
  issue: 11
  year: 2018
  ident: 2041_CR63
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0000000000000433
– volume: 57
  start-page: 462
  issue: 9–10
  year: 2004
  ident: 2041_CR163
  publication-title: Wiad Lek
– volume: 3
  start-page: 114
  issue: 1
  year: 2010
  ident: 2041_CR87
  publication-title: Cancer Prev Res (Phila)
  doi: 10.1158/1940-6207.CAPR-09-0059
– volume: 38
  start-page: 2436
  issue: 12
  year: 1997
  ident: 2041_CR185
  publication-title: J Lipid Res
  doi: 10.1016/S0022-2275(20)30028-6
– volume: 52
  start-page: 105
  year: 2017
  ident: 2041_CR44
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2016.11.009
– volume: 12
  start-page: 78
  issue: 1
  year: 2021
  ident: 2041_CR283
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03389-1
– volume: 36
  start-page: 4089
  issue: 29
  year: 2017
  ident: 2041_CR258
  publication-title: Oncogene
  doi: 10.1038/onc.2017.11
– volume: 42
  start-page: 409
  issue: 5
  year: 2018
  ident: 2041_CR243
  publication-title: Ultrastruct Pathol
  doi: 10.1080/01913123.2018.1522406
– volume: 25
  start-page: 13
  year: 2016
  ident: 2041_CR190
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2016.02.001
– volume: 141
  start-page: 279
  issue: 2
  year: 2017
  ident: 2041_CR33
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30738
– volume: 46
  start-page: 5859
  issue: 6
  year: 2019
  ident: 2041_CR128
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-019-05019-8
– volume: 103
  start-page: 1461
  issue: 19
  year: 2011
  ident: 2041_CR20
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr291
– volume: 74
  start-page: 372
  issue: 4
  year: 2014
  ident: 2041_CR205
  publication-title: Prostate
  doi: 10.1002/pros.22758
– volume: 287
  start-page: 1005
  issue: 5
  year: 2020
  ident: 2041_CR112
  publication-title: FEBS J
  doi: 10.1111/febs.15069
– volume: 11
  start-page: 994
  issue: 7
  year: 2019
  ident: 2041_CR111
  publication-title: Cancers
  doi: 10.3390/cancers11070994
– volume: 42
  start-page: 245
  issue: 4
  year: 2017
  ident: 2041_CR267
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2016.10.004
– volume: 6
  start-page: 16
  year: 2018
  ident: 2041_CR208
  publication-title: Cancer Metab
  doi: 10.1186/s40170-018-0187-2
– volume: 8
  start-page: 1655
  issue: 9
  year: 2017
  ident: 2041_CR123
  publication-title: J Cancer
  doi: 10.7150/jca.19100
– volume: 39
  start-page: 101042831773494
  issue: 10
  year: 2017
  ident: 2041_CR167
  publication-title: Tumour Biol
  doi: 10.1177/1010428317734947
– volume: 20
  start-page: 243
  issue: 3
  year: 2018
  ident: 2041_CR226
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0042-2
– volume: 109
  start-page: 1125
  issue: 9
  year: 2002
  ident: 2041_CR192
  publication-title: J Clin Invest
  doi: 10.1172/JCI0215593
– volume: 29
  start-page: 347
  issue: 5
  year: 2019
  ident: 2041_CR250
  publication-title: Cell Res
  doi: 10.1038/s41422-019-0164-5
– ident: 2041_CR30
  doi: 10.1158/1940-6207.CAPR-20-0123
– volume: 1873
  start-page: 188351
  issue: 2
  year: 2020
  ident: 2041_CR137
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2020.188351
– ident: 2041_CR138
  doi: 10.1016/j.trecan.2020.11.008
– volume: 159
  start-page: 104919
  year: 2020
  ident: 2041_CR252
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2020.104919
– volume: 51
  start-page: 931
  issue: 3
  year: 2017
  ident: 2041_CR124
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2017.4071
– volume: 23
  start-page: 369
  issue: 3
  year: 2016
  ident: 2041_CR251
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2015.158
– volume: 526
  start-page: 660
  issue: 7575
  year: 2015
  ident: 2041_CR271
  publication-title: Nature
  doi: 10.1038/nature15514
– volume: 21
  start-page: 810
  issue: 6
  year: 2019
  ident: 2041_CR27
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-018-1992-3
– volume: 24
  start-page: 833
  issue: 5
  year: 2015
  ident: 2041_CR36
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-15-0052
– volume: 367
  start-page: 462
  issue: 2
  year: 2008
  ident: 2041_CR235
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2007.12.166
– volume: 50 Suppl
  start-page: S15
  issue: Suppl
  year: 2009
  ident: 2041_CR194
  publication-title: J Lipid Res
  doi: 10.1194/jlr.R800054-JLR200
– volume: 61
  start-page: 6020
  issue: 16
  year: 2001
  ident: 2041_CR291
  publication-title: Cancer Res
– volume: 18
  start-page: 2825
  issue: 3
  year: 2019
  ident: 2041_CR215
  publication-title: Oncol Lett
– volume: 23
  start-page: 161
  issue: 1
  year: 1995
  ident: 2041_CR154
  publication-title: Biochem Soc Trans
  doi: 10.1042/bst0230161
– volume: 76
  start-page: 59
  issue: 1
  year: 2016
  ident: 2041_CR130
  publication-title: Braz J Biol
  doi: 10.1590/1519-6984.11914
– volume: 7
  start-page: 44841
  year: 2017
  ident: 2041_CR165
  publication-title: Sci Rep
  doi: 10.1038/srep44841
– volume: 106
  start-page: e696
  issue: 2
  year: 2021
  ident: 2041_CR306
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/clinem/dgaa877
– volume: 12
  start-page: 250
  issue: 1
  year: 2016
  ident: 2041_CR94
  publication-title: Oncol Lett
  doi: 10.3892/ol.2016.4569
– volume: 54
  start-page: 2050
  issue: 10
  year: 2016
  ident: 2041_CR129
  publication-title: Pharm Biol
  doi: 10.3109/13880209.2016.1141221
– volume: 16
  start-page: 718
  issue: 11
  year: 2016
  ident: 2041_CR142
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.76
– volume: 22
  start-page: 1139
  issue: 8
  year: 2001
  ident: 2041_CR160
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/22.8.1139
– volume: 84
  start-page: 886
  issue: 7
  year: 2001
  ident: 2041_CR55
  publication-title: Br J Cancer
  doi: 10.1054/bjoc.2000.1716
– volume: 6
  start-page: 19435
  year: 2016
  ident: 2041_CR145
  publication-title: Sci Rep
  doi: 10.1038/srep19435
– volume: 8
  start-page: 394
  year: 2018
  ident: 2041_CR141
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00394
– volume: 168
  start-page: 250
  issue: 3
  year: 2008
  ident: 2041_CR67
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwn141
– volume: 60
  start-page: 240
  issue: 3
  year: 2013
  ident: 2041_CR107
  publication-title: Neoplasma
  doi: 10.4149/neo_2013_032
– volume: 101
  start-page: 689
  issue: 4
  year: 2017
  ident: 2041_CR13
  publication-title: Med Clin North Am
  doi: 10.1016/j.mcna.2017.03.001
– volume: 12
  start-page: 1410
  issue: 6
  year: 2020
  ident: 2041_CR200
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12061410
– volume: 20
  start-page: 320
  issue: 6
  year: 2020
  ident: 2041_CR92
  publication-title: Oncol Lett
  doi: 10.3892/ol.2020.12183
– volume: 35
  start-page: 256
  issue: 3
  year: 2018
  ident: 2041_CR72
  publication-title: Balkan Med J
  doi: 10.4274/balkanmedj.2017.0604
– volume: 25
  start-page: 1285
  issue: 12
  year: 2015
  ident: 2041_CR273
  publication-title: Cell Res
  doi: 10.1038/cr.2015.139
– volume: 27
  start-page: 673
  issue: 9
  year: 2017
  ident: 2041_CR278
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2017.05.005
– volume: 31
  start-page: 377
  issue: 4
  year: 2020
  ident: 2041_CR164
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0000000000000885
– volume: 11
  start-page: 994
  issue: 7
  year: 2019
  ident: 2041_CR158
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11070994
– volume: 123
  start-page: 951
  issue: 4
  year: 2008
  ident: 2041_CR166
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23593
– volume: 2
  start-page: 80
  issue: 2
  year: 2006
  ident: 2041_CR229
  publication-title: Autophagy
  doi: 10.4161/auto.2.2.2460
– volume: 11
  start-page: 574068
  year: 2020
  ident: 2041_CR171
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.574068
– volume: 11
  start-page: 7231
  year: 2019
  ident: 2041_CR82
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S212643
– volume: 80
  start-page: 175
  issue: 2
  year: 2020
  ident: 2041_CR297
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0644
– volume: 484
  start-page: 50
  year: 2020
  ident: 2041_CR108
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2020.05.005
– volume: 14
  start-page: 273
  issue: 7
  year: 2004
  ident: 2041_CR262
  publication-title: Trends Cardiovasc Med
  doi: 10.1016/j.tcm.2004.08.003
– volume: 8
  start-page: 17833
  issue: 11
  year: 2017
  ident: 2041_CR77
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14868
– volume: 12
  start-page: 691
  issue: 8
  year: 2011
  ident: 2041_CR89
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.12.8.15978
– volume: 8
  start-page: 609
  issue: 6
  year: 2008
  ident: 2041_CR153
  publication-title: Mini Rev Med Chem
  doi: 10.2174/138955708784534436
– volume: 12
  start-page: 5252
  issue: 9
  year: 2020
  ident: 2041_CR247
  publication-title: Am J Transl Res
– volume: 10
  start-page: 959
  issue: 1
  year: 2020
  ident: 2041_CR105
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-57707-2
– ident: 2041_CR174
  doi: 10.1002/jcb.27544
– volume: 17
  start-page: 110
  issue: 2
  year: 2016
  ident: 2041_CR143
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2015.11
– volume: 8
  start-page: 1617
  issue: 6
  year: 2017
  ident: 2041_CR300
  publication-title: Stem Cell Rep
  doi: 10.1016/j.stemcr.2017.04.025
– volume: 131
  start-page: e142616
  issue: 1
  year: 2021
  ident: 2041_CR313
  publication-title: J Clin Invest
  doi: 10.1172/JCI142616
– volume: 7
  start-page: e45354
  issue: 9
  year: 2012
  ident: 2041_CR244
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0045354
– volume: 122
  start-page: 661
  issue: 3
  year: 2010
  ident: 2041_CR204
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-009-0594-8
– volume: 356
  start-page: 192
  issue: 2 Pt A
  year: 2015
  ident: 2041_CR140
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2014.01.013
– volume: 26
  start-page: 191
  issue: 2
  year: 2018
  ident: 2041_CR83
  publication-title: Saudi Pharm J
  doi: 10.1016/j.jsps.2017.12.012
– volume: 12
  start-page: 4645
  year: 2020
  ident: 2041_CR91
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S247876
– volume: 154
  start-page: 432
  issue: 2
  year: 2019
  ident: 2041_CR134
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2019.05.022
– volume: 40
  start-page: 1697
  issue: 8
  year: 2018
  ident: 2041_CR46
  publication-title: Head Neck
  doi: 10.1002/hed.25152
– volume: 290
  start-page: 1721
  issue: 5497
  year: 2000
  ident: 2041_CR195
  publication-title: Science
  doi: 10.1126/science.290.5497.1721
– volume: 12
  start-page: 597
  issue: 7
  year: 2020
  ident: 2041_CR70
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12070597
– volume: 70
  start-page: 7699
  issue: 19
  year: 2010
  ident: 2041_CR240
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1626
– volume: 63
  start-page: 1186
  issue: 5
  year: 1984
  ident: 2041_CR187
  publication-title: Blood
  doi: 10.1182/blood.V63.5.1186.1186
– volume: 585
  start-page: 113
  issue: 7823
  year: 2020
  ident: 2041_CR255
  publication-title: Nature
  doi: 10.1038/s41586-020-2623-z
– volume: 115
  start-page: 129
  issue: 1
  year: 2016
  ident: 2041_CR57
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.149
– volume: 367
  start-page: 1792
  issue: 19
  year: 2012
  ident: 2041_CR56
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1201735
– volume: 10
  start-page: e018393
  issue: 2
  year: 2021
  ident: 2041_CR314
  publication-title: J Am Heart Assoc.
  doi: 10.1161/JAHA.119.018393
– volume: 144
  start-page: 646
  issue: 5
  year: 2011
  ident: 2041_CR135
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 143
  start-page: 6
  year: 2019
  ident: 2041_CR146
  publication-title: Steroids
  doi: 10.1016/j.steroids.2018.12.003
– volume: 765
  start-page: 415
  year: 2015
  ident: 2041_CR239
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2015.09.004
– volume: 293
  start-page: 26
  year: 2020
  ident: 2041_CR282
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2019.11.033
– volume: 547
  start-page: 99
  issue: 7661
  year: 2017
  ident: 2041_CR276
  publication-title: Nature
  doi: 10.1038/nature22393
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 2041_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 17
  start-page: 88
  issue: 1
  year: 2008
  ident: 2041_CR90
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-07-0531
– volume: 73
  start-page: 1214
  issue: 11
  year: 2013
  ident: 2041_CR66
  publication-title: Prostate
  doi: 10.1002/pros.22671
– volume: 83
  start-page: 162
  issue: 2
  year: 1999
  ident: 2041_CR183
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19991008)83:2<162::AID-IJC3>3.0.CO;2-W
– volume: 50
  start-page: 2822
  issue: 16
  year: 2014
  ident: 2041_CR51
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2014.08.005
– volume: 13
  start-page: 133
  year: 2015
  ident: 2041_CR48
  publication-title: J Transl Med
  doi: 10.1186/s12967-015-0486-0
– volume: 526
  start-page: 666
  issue: 7575
  year: 2015
  ident: 2041_CR274
  publication-title: Nature
  doi: 10.1038/nature15541
– volume: 250
  start-page: 220
  issue: 2
  year: 2007
  ident: 2041_CR73
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2006.10.009
– volume: 19
  start-page: 49
  year: 2017
  ident: 2041_CR237
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2017.04.017
– volume: 35
  start-page: 23
  year: 2016
  ident: 2041_CR246
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-016-0303-5
– volume: 110
  start-page: 597
  issue: 5
  year: 2002
  ident: 2041_CR148
  publication-title: J Clin Invest
  doi: 10.1172/JCI0216390
– volume: 103
  start-page: 825
  issue: 4
  year: 2008
  ident: 2041_CR117
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2007.01773.x
– volume: 32
  start-page: 171
  issue: 4
  year: 2011
  ident: 2041_CR269
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2011.02.002
– volume: 7
  start-page: 82482
  issue: 50
  year: 2016
  ident: 2041_CR287
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12694
– volume: 39
  start-page: 211
  issue: 2
  year: 2013
  ident: 2041_CR231
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.07.017
– volume: 23
  start-page: 630
  issue: 4
  year: 2020
  ident: 2041_CR50
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/s41391-020-0221-7
– volume: 368
  start-page: 576
  issue: 6
  year: 2013
  ident: 2041_CR61
  publication-title: N Engl J Med
– volume: 71
  start-page: 516
  issue: 3
  year: 2019
  ident: 2041_CR54
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.04.021
– volume: 10
  start-page: 205
  issue: 3
  year: 2010
  ident: 2041_CR189
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2795
– volume: 16
  start-page: 1268
  issue: 12
  year: 2011
  ident: 2041_CR113
  publication-title: Apoptosis
  doi: 10.1007/s10495-011-0649-2
– volume: 547
  start-page: 453
  issue: 7664
  year: 2017
  ident: 2041_CR264
  publication-title: Nature
  doi: 10.1038/nature23007
– volume: 9
  start-page: 265
  issue: 1
  year: 2019
  ident: 2041_CR286
  publication-title: Theranostics
  doi: 10.7150/thno.27246
– volume: 10
  start-page: 499
  year: 2020
  ident: 2041_CR173
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.00499
– volume: 5
  start-page: 579
  issue: 8
  year: 2005
  ident: 2041_CR9
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800905774932824
– volume: 16
  start-page: 182
  issue: 1
  year: 2017
  ident: 2041_CR120
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-16-0499
– volume: 23
  start-page: 225
  issue: 2
  year: 2016
  ident: 2041_CR265
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2015.11.016
– volume: 109
  start-page: 573
  issue: 3
  year: 2008
  ident: 2041_CR21
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-007-9683-8
– volume: 14
  start-page: 2533
  issue: 10
  year: 2020
  ident: 2041_CR307
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12775
– volume: 10
  start-page: 51
  issue: 1
  year: 2006
  ident: 2041_CR233
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2006.06.001
– volume: 45
  start-page: 101588
  issue: 5
  year: 2021
  ident: 2041_CR32
  publication-title: Clin Res Hepatol Gastroenterol
  doi: 10.1016/j.clinre.2020.101588
– volume: 29
  start-page: 431
  issue: 4
  year: 2009
  ident: 2041_CR206
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.108.179564
– volume: 16
  start-page: 319
  issue: 3
  year: 2013
  ident: 2041_CR277
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2013.04.004
– volume: 164
  start-page: 1
  issue: 1
  year: 2017
  ident: 2041_CR64
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-017-4246-0
– volume: 28
  start-page: 1171
  issue: 12
  year: 2018
  ident: 2041_CR281
  publication-title: Cell Res
  doi: 10.1038/s41422-018-0090-y
– volume: 12
  start-page: 725
  issue: 2
  year: 2016
  ident: 2041_CR76
  publication-title: J Cancer Res Ther
  doi: 10.4103/0973-1482.146127
– volume: 582
  start-page: 2589
  issue: 17
  year: 2008
  ident: 2041_CR81
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2008.06.034
– volume: 18
  start-page: 3337
  issue: 23
  year: 2019
  ident: 2041_CR133
  publication-title: Cell Cycle (Georgetown, Tex)
  doi: 10.1080/15384101.2019.1676581
– volume: 352
  start-page: aaf2154
  issue: 6281
  year: 2016
  ident: 2041_CR266
  publication-title: Science
  doi: 10.1126/science.aaf2154
– volume: 4
  start-page: 1008
  issue: 6
  year: 1992
  ident: 2041_CR157
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/0955-0674(92)90133-W
– volume: 43
  start-page: 395
  issue: 5
  year: 2011
  ident: 2041_CR119
  publication-title: Dig Liver Dis
  doi: 10.1016/j.dld.2011.01.010
– volume: 26
  start-page: 209
  issue: 1
  year: 2020
  ident: 2041_CR85
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-018-0415-7
– volume: 80
  start-page: 189
  issue: 2
  year: 2020
  ident: 2041_CR169
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0650
– volume: 22
  start-page: 5337
  issue: 21
  year: 2016
  ident: 2041_CR202
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2973
– volume: 91
  start-page: 204
  issue: 2
  year: 2020
  ident: 2041_CR15
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2019-320893
– volume: 73
  start-page: 253
  issue: 2
  year: 1994
  ident: 2041_CR180
  publication-title: Cancer
  doi: 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F
– volume: 14
  start-page: 6243
  issue: 5
  year: 2017
  ident: 2041_CR78
  publication-title: Oncol Lett
– volume: 19
  start-page: 75
  issue: 2
  year: 2014
  ident: 2041_CR234
  publication-title: J Cancer Prev
  doi: 10.15430/JCP.2014.19.2.75
– volume: 10
  start-page: e0139289
  issue: 10
  year: 2015
  ident: 2041_CR38
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0139289
– volume: 5
  start-page: 1046
  issue: 7
  year: 2009
  ident: 2041_CR230
  publication-title: Autophagy
  doi: 10.4161/auto.5.7.9444
– volume: 43
  start-page: 808
  issue: 5
  year: 2005
  ident: 2041_CR97
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2005.04.010
– ident: 2041_CR28
  doi: 10.1093/jnci/djw275
– volume: 14
  start-page: 7993
  issue: 6
  year: 2017
  ident: 2041_CR114
  publication-title: Oncol Lett
– volume: 5
  start-page: 166
  issue: 1
  year: 2020
  ident: 2041_CR285
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00280-x
– volume: 111
  start-page: 2965
  issue: 8
  year: 2020
  ident: 2041_CR304
  publication-title: Cancer Sci
  doi: 10.1111/cas.14493
– volume: 21
  start-page: 4652
  issue: 20
  year: 2015
  ident: 2041_CR104
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-3368
– volume: 8
  start-page: e67993
  issue: 6
  year: 2013
  ident: 2041_CR211
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0067993
– volume: 14
  start-page: 1180
  issue: 5
  year: 2010
  ident: 2041_CR11
  publication-title: J Cell Mol Med
– volume: 184
  start-page: 13
  year: 2018
  ident: 2041_CR245
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2017.10.017
– volume: 1830
  start-page: 4053
  issue: 8
  year: 2013
  ident: 2041_CR95
  publication-title: Biochem Biophys Acta
  doi: 10.1016/j.bbagen.2013.04.011
– volume: 9
  start-page: 5383
  year: 2016
  ident: 2041_CR101
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S106906
– volume: 8
  start-page: 48972
  issue: 30
  year: 2017
  ident: 2041_CR197
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16903
– volume: 8
  start-page: e001361
  issue: 2
  year: 2020
  ident: 2041_CR305
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001361
– volume: 6
  start-page: e28813
  issue: 12
  year: 2011
  ident: 2041_CR12
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0028813
– volume: 117
  start-page: 4158
  issue: 8
  year: 2020
  ident: 2041_CR170
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1917938117
– volume: 38
  start-page: 261
  issue: 4
  year: 2017
  ident: 2041_CR279
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2017.01.003
– volume: 22
  start-page: 749
  issue: 5
  year: 2010
  ident: 2041_CR80
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2009.12.010
– volume: 23
  start-page: 8606
  issue: 34
  year: 2005
  ident: 2041_CR65
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.02.7045
– volume: 75
  start-page: 811
  issue: 9
  year: 1993
  ident: 2041_CR182
  publication-title: Biochimie
  doi: 10.1016/0300-9084(93)90132-C
– volume: 6
  start-page: 41
  issue: 1
  year: 2020
  ident: 2041_CR261
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.9b01063
– volume: 17
  start-page: 1553
  issue: 6
  year: 2011
  ident: 2041_CR53
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2525
– volume: 12
  start-page: 401
  issue: 6
  year: 2012
  ident: 2041_CR228
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3262
– volume: 11
  start-page: 678
  issue: 3
  year: 2021
  ident: 2041_CR256
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-19-1500
– volume: 8
  start-page: e2626
  issue: 2
  year: 2017
  ident: 2041_CR100
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.472
– volume: 36
  start-page: 61
  issue: 1
  year: 2003
  ident: 2041_CR181
  publication-title: Clin Biochem
  doi: 10.1016/S0009-9120(02)00421-6
– volume: 20
  start-page: 703
  issue: 1
  year: 2020
  ident: 2041_CR175
  publication-title: BMC Cancer
  doi: 10.1186/s12885-020-07164-x
– volume: 40
  start-page: 2258
  issue: 12
  year: 2021
  ident: 2041_CR220
  publication-title: Oncogene
  doi: 10.1038/s41388-021-01701-z
SSID ssj0061919
Score 2.6595342
SecondaryResourceType review_article
Snippet As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects...
Abstract As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 241
SubjectTerms Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biosynthesis
Breast cancer
Cancer
Cancer therapies
Cardiovascular disease
Cardiovascular diseases
Chemotherapy
Cholesterol
Clinical trials
Cytotoxicity
Drug Repositioning - methods
Drug repurposing
Drug therapy
Drugs
Epidemiology
Gastric cancer
Health aspects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Lipids
Liver cancer
Medical prognosis
Meta-analysis
Mevalonate pathway
Morbidity
Mortality
Neoplasms - drug therapy
Oncology, Experimental
Pancreatic cancer
Population
Prostate cancer
Review
Statins
Synergistic antitumor
Tumor microenvironment
Tumor Microenvironment - drug effects
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9BLadKmcZo0DhQCLSaWrIfVWxq6LIH01EBuQs82ULxhH_-_M7LXrAm0l16tMay-0Wi-WWs-EfIxtcoKDQHoUx0qblmqXAi-0kBNLYuWuhabk---y_k9v30QDztXfeGZsF4euAfuSjvYTXT0kWL9xGoHBQ9wZmAFKUUtsxIo5LxtMdXvwVAVUL1tkWnl1YriB8AKjyNgMyit2CQNZbX-53vyTlKaHpjcyUCz1-TVQB3L6_4nH5AXsTsk-3fDx_E35BMSx8du9aW05TI-AYKLVQxlWG5-lutFmbAMLz16efmW3M--_biZV8NVCJWXsl4Dfo43nnprRbAwca6TVc7RBIzfec1S7VUdlbC8kbZV0TeuaUXUlAWomLhrjshet-jiMSkT57Vzug6tTJCZqBYiACsAYma9904VhG6RMX7QCcfrKn6bXC-00vRoGkDTZDQNK8jn8Z2nXiXjr9ZfEfDREhWu8wPwuxn8bv7l94Kco7tM3y46xqm5loqhYA-nBbnMFhipMAFvh4YDgAE1ryaWpxNLiDA_Hd4uCTNE-MoAVWR4j3wDwxfjML6Jp9a6uNigjcBO50YAqO_6FTROGh7X-PdAQdRkbU1QmY50j7-y_ncLTmeSnfwPGN-TlyyHhaoYPyV76-UmngHNWrsPOaL-AFVTIK0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ta9YwEA9jgvhFfLc6tYIgKNEmTZNGEJniGMLjJx_Yt5CkyTYY7ezzPKD_vXfpCyuOfW0upfn1rne_JndHyJtYK1tpMEAfi4YKyyN1TeOphtDU8mCZqzE5efVTHq_Fj5PqZI9M7Y5GADfXUjvsJ7XuLz78-f33Cxj852Twtfy4Ybi9R_GwAaZ6Mgqf5FvgmRQa6krMuwrAFVKjD_CYkmKcPyXRXHuPhaNK9fz__2pfcVvLI5VXfNTRPXJ3DC7zw0Eb7pO90D4gt1fj9vlD8g5Dy_N28ym3eR8uAeNuE5q86Xen-bbLIxL13KMe9I_I-uj7r2_HdGyWQL2UxRYQdqL0zFtbNTbGIHS0yjkWgRM4r3ksvCqCqqwopa1V8KUr6ypoxhvgVMKVj8l-27XhKcmjEIVzumhqGcF3MV1VDcQNELpZ771TGWETMsaPlcSxocWFSYyilmZA0wCaJqFpeEbez3MuhzoaN0p_RcBnSayBnS50_akZTcpoB35GBx8YMmteOKDCwKYgXoTlayky8gpflxkSSmdLNodScSzpI1hG3iYJ1C5YgLdjSgLAgFWxFpIHC0mwQb8cnlTCTCpsIJjk2Gm-hOHX8zDOxHNtbeh2KFNhLnRZAahPBg2aFw2XC_yBkBG10K0FKsuR9vwsVQiv4aVzyZ_d_FjPyR2eFF5RLg7I_rbfhRcQYm3dy2Q3_wD0yB3K
  priority: 102
  providerName: Scholars Portal
Title Statins: a repurposed drug to fight cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/34303383
https://www.proquest.com/docview/2562465131
https://www.proquest.com/docview/2555334357
https://pubmed.ncbi.nlm.nih.gov/PMC8306262
https://doaj.org/article/9beb19ece1274720b402642059ffe964
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0BfFF_Da1nhEEQVmabDabxBfpSUsRrkixcPiy7GdbkORM7v7_zuztxQahL3nITiD725mdmd35IOSjrytVNiCAxmeWcsU81dYa2oBpqphTua4xOXlxLs4u-Y9luYwHbkMMq9ztiWGjtp3BM_IjUM0M-3YX-bfVX4pdo_B2NbbQeEj2sXQZhnRVy9HhAt8gNPYADSko2vW7pJlaHA05XglSDFDA9NCcsoliCvX7_9-l76ipaQjlHZ10-pQ8icZkerxd_WfkgWufk0eLeF3-gnxGU_KmHb6mKu3dCjDtBmdT22-u0nWXenTMU4Pr3r8kl6cnv76f0dgcgRohsjUgqnlhcqNUaZX3jjdeVVrnHnwAbRrmM1NlrioVL4SqK2cKXdSla3JmwYfiunhF9tqudW9I6jnPtG4yWwsPugqALC3YCWCqKWOMrhKS75CRJlYOxwYWf2TwIGoht2hKQFMGNCVLyJfxm9W2bsa91HMEfKTEmtfhRddfyShCstGgVxpnXI6eNMs0uL7gPYF9CNNvBE_Ie1wuuU0gHSVXHouKYQkfnifkU6BA2YUJGBVTEAAGrII1oTycUILMmenwjiVklPlB_uPQhHwYh_FLjGNrXbdBmhJzn4sSQH295aBx0vA6wwODhFQT3pqgMh1pb65DRfAaFp0JdnD_b70lj1lg-Ioyfkj21v3GvQOTaq1nQW5mZH9-cv7zYhYOJuC54DU8L-a_bwEHbB8n
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ra9UwFD_MDdQv4tvqdBUUQSlr0jRtBZFNN-7c7kVkg33LkjSZA2mv94H4T_k3ek4f1xVh3_a1OS3NL-eZ5JwD8MrnmU4LFEDr4zISmvvIlKWNCnRNNXeamZySk8cTOToRX07T0zX40-fC0LXKXic2irqsLe2Rb6Np5tS3O2Efpz8j6hpFp6t9C42WLQ7d718Yss0_HHzG9X3N-f7e8adR1HUViKyU8QJ_xYjEMqt1WmrvnSi8zoxhHp1nYwvuY5vFLku1SKTOM2cTk-SpKxgvMfgQJsHv3oANHI1REWzs7k2-fut1P0YjTSsRtMkyokiiT9PJ5fac0SFkRFciKCGVRXxgCpuOAf_bhUuGcXhp85IV3L8Ldzr3Ndxp-e0erLnqPtwcdwf0D-AtOa8X1fx9qMOZm-Iq1nNXhuVseR4u6tDTVkBoidNmD-HkWoB7BOtVXbknEHohYmOKuMylR-vIijQt0TNB51Bba00WAOuRUbarVU4tM36oJmbJpWrRVIimatBUPIB3q3embaWOK6l3CfAVJVXZbh7Us3PVCa0qDFqywlnHKHbnscFgG-M19Ehx-oUUAWzRcqk2ZXWlK9SOzDgVDRIsgDcNBWkLnIDVXdIDwkB1twaUmwNKlHI7HO5ZQnVaZq7-yUQAL1fD9CbdnKtcvSSalLKtkxRBfdxy0GrS-DimLYoAsgFvDVAZjlQX35sa5DkuOpf86dW_tQW3RsfjI3V0MDl8Brd5w_xZxMUmrC9mS_ccHbqFedFJUQhn1y24fwGv9lrO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Statins%3A+a+repurposed+drug+to+fight+cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Jiang%2C+Wen&rft.au=Jin-Wei%2C+Hu&rft.au=Xu-Ran%2C+He&rft.au=Wei-Lin%2C+Jin&rft.date=2021-07-24&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=40&rft.spage=1&rft_id=info:doi/10.1186%2Fs13046-021-02041-2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon